-
公开(公告)号：US20250026808A1
公开(公告)日：2025-01-23
申请号：US18898069
申请日：2024-09-26
Applicant: CELLECTIS SA
Inventor： Julianne SMITH , Phillippe DUCHATEAU , Murielle DERRIEN
IPC: C07K14/705 , A61K31/365 , A61K39/00 , A61K39/395 , A61P35/02 , C07K14/725 , C07K16/28 , C12N5/0783
Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
-
公开(公告)号：US20210000869A9
公开(公告)日：2021-01-07
申请号：US16365588
申请日：2019-03-26
Applicant: CELLECTIS
Inventor： Roman Galetto , Julianne SMITH , Andrew SCHARENBERG , Cecile SCHIFFER-MANNIOUI
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells; expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
-
13.发明申请公开(公告)号：US20190216854A1
公开(公告)日：2019-07-18
申请号：US16361438
申请日：2019-03-22
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
CPC classification number: A61K35/17 , A61K38/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
14.发明申请公开(公告)号：US20180021379A1
公开(公告)日：2018-01-25
申请号：US15711289
申请日：2017-09-21
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: C07K14/725 , C12N5/0783 , C07K14/705 , C07K16/28 , A61K38/00
CPC classification number: A61K35/17 , A61K38/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
公开(公告)号：US20160222410A1
公开(公告)日：2016-08-04
申请号：US14915434
申请日：2014-09-02
Applicant: CELLECTIS
Inventor： Andrew SCHARENBERG , Julianne SMITH , Roman GALETTO
CPC classification number: C12N15/86 , C12N7/00 , C12N2740/17043 , C12N2740/17052
Abstract: The present invention relates to viral transformation method, particularly foamy virus-mediated transformation method. The present invention relates to the transfer of transgene into cells by the safe and efficient transfer of RNA encoding foamy components. The present invention has therefore therapeutic interest, especially in the field of gene therapy.
Abstract translation: 本发明涉及病毒转化方法，特别是泡沫病毒介导的转化方法。 本发明涉及通过安全有效地转移编码泡沫组分的RNA将转基因转移到细胞中。 因此，本发明具有治疗兴趣，特别是在基因治疗领域。
-
Patent Agency Ranking
公开(公告)号：US20160138047A1
公开(公告)日：2016-05-19
申请号：US14898148
申请日：2014-06-13
Applicant: CELLECTIS
Inventor： Philippe DUCHATEAU , Sylvain ARNOULD , Julianne SMITH
CPC classification number: C12N15/86 , C07K14/00 , C07K2319/80 , C12N7/00 , C12N9/22 , C12N2740/15043 , C12Y301/21004
Abstract: The present invention is in the field of the gene editing molecular tools. The present invention relates to rewritten nucleic acid sequences encoding repeated DNA recognition motifs of TALE (Transcription Activator-Like Effector) proteins. These nucleic acid sequences allow assembly and cloning of TALE repeats in any type of vectors, especially viral vectors. The invention thereby contributes to improving gene targeting in cells using TALE derived proteins, in particular for genetic regulation or modification. The present invention is particularly drawn to virus mediated transformation methods, by providing vectors, compositions and kits including said new nucleic acid sequences.
Abstract translation: 本发明是在基因编辑领域的分子工具。 本发明涉及编码TALE（转录激活子样效应物）蛋白的重复DNA识别基序的重写核酸序列。 这些核酸序列允许在任何类型的载体，特别是病毒载体中组装和克隆TALE重复。 因此，本发明有助于使用TALE衍生的蛋白质改善细胞中的基因靶向，特别是用于遗传调控或修饰。 通过提供载体，组合物和试剂盒，包括所述新的核酸序列，本发明特别地涉及病毒介导的转化方法。
-
17.发明申请公开(公告)号：US20220348955A1
公开(公告)日：2022-11-03
申请号：US17848590
申请日：2022-06-24
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: C12N15/85 , A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
18.发明申请公开(公告)号：US20200281979A1
公开(公告)日：2020-09-10
申请号：US16876079
申请日：2020-05-17
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
19.发明申请公开(公告)号：US20180360883A1
公开(公告)日：2018-12-20
申请号：US16027629
申请日：2018-07-05
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K16/28 , C07K14/725
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
20.发明申请公开(公告)号：US20180009895A1
公开(公告)日：2018-01-11
申请号：US15546633
申请日：2016-01-25
Applicant: Cellectis
Inventor： Julianne SMITH , Julien VALTON , Philippe DUCHATEAU , Alexandre JUILLERAT , Arvind RAJPAL , Barbra Johnson SASU
IPC: C07K16/28 , A61K39/00 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N5/00
CPC classification number: C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.018 seconds)
